Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1987-12-11
|
| pubmed:abstractText |
Eleven patients with intracranial tumors were investigated with MR imaging at different dose levels of gadolinium-DTPA to determine a safe and effective dose for imaging intracranial tumors. The patients were divided into two groups. Baseline spin-echo images were obtained with a repetition time of 800 msec and an echo time of 35 msec, and a total of 0.1 mmol of gadolinium-DTPA/kg (six patients) or 0.2 mmol gadolinium-DTPA/kg (five patients) was injected according to a fractionated incremental dose regime (0.025, 0.025, and 0.05 mmol/kg and 0.05, 0.05, and 0.1 mmol/kg, respectively). Postcontrast MR was performed after each injection. In group 1 the best visualization was achieved after the third injection in four cases. In one glioblastoma and in a pituitary adenoma tumor margins were well defined at lower dose levels. In group 2, with five patients, the total dose of 0.2 mmol of gadolinium-DTPA/kg (0.05, 0.05, and 0.1) significantly improved tumor visualization after the third injection in only one patient with multiple metastases. No short-term side effects were encountered. In a range of parameters measured in both serum and whole blood, slight transient elevation of serum iron levels was the only appreciable change. As a result of our investigation we conclude that 0.1 mmol of gadolinium-DTPA/kg is a safe and suitable dose for brain-tumor imaging. In selected cases of 0.2 mmol/kg may increase the diagnostic yield.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Contrast Media,
http://linkedlifedata.com/resource/pubmed/chemical/Gadolinium,
http://linkedlifedata.com/resource/pubmed/chemical/Gadolinium DTPA,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Pentetic Acid
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0195-6108
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
803-15
|
| pubmed:dateRevised |
2008-2-14
|
| pubmed:meshHeading |
pubmed-meshheading:2823588-Adenoma,
pubmed-meshheading:2823588-Adult,
pubmed-meshheading:2823588-Aged,
pubmed-meshheading:2823588-Animals,
pubmed-meshheading:2823588-Brain Neoplasms,
pubmed-meshheading:2823588-Contrast Media,
pubmed-meshheading:2823588-Dogs,
pubmed-meshheading:2823588-Drug Administration Schedule,
pubmed-meshheading:2823588-Female,
pubmed-meshheading:2823588-Gadolinium,
pubmed-meshheading:2823588-Gadolinium DTPA,
pubmed-meshheading:2823588-Glioblastoma,
pubmed-meshheading:2823588-Glioma,
pubmed-meshheading:2823588-Humans,
pubmed-meshheading:2823588-Magnetic Resonance Imaging,
pubmed-meshheading:2823588-Male,
pubmed-meshheading:2823588-Middle Aged,
pubmed-meshheading:2823588-Neuroma, Acoustic,
pubmed-meshheading:2823588-Organometallic Compounds,
pubmed-meshheading:2823588-Pentetic Acid,
pubmed-meshheading:2823588-Pituitary Neoplasms
|
| pubmed:articleTitle |
Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors.
|
| pubmed:affiliation |
Department of Radiology, Schering AG, Berlin, West Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|